1 results
24 - Animal models of Parkinson's disease
-
- By Anumantha G. Kanthasamy, Department of Biomedical Sciences 2062 Veterinary Medicine Building Iowa State University Ames, IA 50011 USA, Siddharth Kaul, Department of Biomedical Sciences 2062 Veterinary Medicine Building Iowa State University Ames, IA 50011 USA
- Edited by Turgut Tatlisumak, Marc Fisher
-
- Book:
- Handbook of Experimental Neurology
- Published online:
- 04 November 2009
- Print publication:
- 05 October 2006, pp 411-437
-
- Chapter
- Export citation
-
Summary
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by the gradual dopaminergic loss in the substantia nigra of the midbrain region. Development of PD can be sporadic or can be associated with genetic mutations and deficiencies, or may result from the combination of these two precipitating factors. The pathogenesis of PD has been studied in numerous experimental models developed to replicate the salient features of the disease in a controlled environment. Although no single model exists today that mimics all the neurological and neuropathological features of PD, each model presents a particular aspect of the disease process induced either by natural or artificial toxic agents or by genetically induced deficiencies in experimental animals. Epidemiological and laboratory results suggest that environmental factors play a predominant role in the induction and propagation of dopaminergic degeneration. However, numerous familial cases indicate that development of PD might be aggravated by pre-existing genetic deficiencies that act as predisposing factors. This chapter describes in detail the extensive research conducted using animal and tissue-culture models of Parkinson's disease induced by both toxins and genetic manipulation. Furthermore, salient experimental findings are thoroughly described with regard to current perspectives on neurotoxic mechanisms of genetic variations and environmental toxins.
6-Hydroxydopamine model of PD
6-Hydroxydopamine (6-OHDA) was first demonstrated to effectively replicate Parkinsonian neurotoxic pathology in rats by stereotaxic nigral injection in rats as early as 1975.